{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:45:53Z","timestamp":1792525553910,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-025-00777-6","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T23:34:26Z","timestamp":1764718466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"27","author":[{"given":"Basir Afzaal","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anum","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsalan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishrat","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Saeeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansa","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nabeel","family":"Saddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"777_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2213-2600(23)00230-8","volume":"11","author":"P Venkatesan","year":"2023","unstructured":"Venkatesan P. 2023 GINA report for asthma. Lancet Respir Med. 2023;11:589. https:\/\/doi.org\/10.1016\/S2213-2600(23)00230-8.","journal-title":"Lancet Respir Med"},{"key":"777_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nm.2678","volume":"18","author":"SE Wenzel","year":"2012","unstructured":"Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716\u201325. https:\/\/doi.org\/10.1038\/nm.2678.","journal-title":"Nat Med"},{"key":"777_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1471-4914(02)02302-X","volume":"8","author":"PS Foster","year":"2002","unstructured":"Foster PS, Hogan SP, Yang M, Mattes J, Young IG, Matthaei KI, et al. Interleukin-5 and eosinophils as therapeutic targets for asthma. Trends Mol Med. 2002;8:162\u20137. https:\/\/doi.org\/10.1016\/S1471-4914(02)02302-X.","journal-title":"Trends Mol Med"},{"key":"777_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/ni.3049","volume":"16","author":"BN Lambrecht","year":"2015","unstructured":"Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45\u201356. https:\/\/doi.org\/10.1038\/ni.3049.","journal-title":"Nat Immunol"},{"key":"777_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050384","volume":"13","author":"M Hussain","year":"2024","unstructured":"Hussain M, Liu G. Eosinophilic asthma: pathophysiology and therapeutic horizons. Cells. 2024;13:384. https:\/\/doi.org\/10.3390\/cells13050384.","journal-title":"Cells"},{"key":"777_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/14712598.2018.1492540","volume":"18","author":"SS Patel","year":"2018","unstructured":"Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. 2018;18:747\u201354. https:\/\/doi.org\/10.1080\/14712598.2018.1492540.","journal-title":"Expert Opin Biol Ther"},{"key":"777_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(12)60988-X.","journal-title":"Lancet"},{"key":"777_CR8","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","volume":"391","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med. 2024;391:2337\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2406673.","journal-title":"N Engl J Med"},{"key":"777_CR9","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"key":"777_CR10","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: Cochrane Book Series n.d."},{"key":"777_CR11","unstructured":"WebPlotDigitizer. accessed August 4, n.d.\u00a02024.\u00a0https:\/\/web.eecs.utk.edu\/~dcostine\/personal\/PowerDeviceLib\/DigiTest\/index.html\u00a0"},{"key":"777_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A. Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol. 2024;24:243. https:\/\/doi.org\/10.1186\/s12874-024-02356-6.","journal-title":"BMC Med Res Methodol"},{"key":"777_CR13","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"777_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk\u2010of\u2010bias visualization (robvis): an R package and Shiny web app for visualizing risk\u2010of\u2010bias assessments. Res Synth Methods. 2021;12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods"},{"key":"777_CR15","unstructured":"GlaxoSmithKline. A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype. clinicaltrials.gov; 2024."},{"key":"777_CR16","unstructured":"2024 GINA Main Report. Glob Initiat Asthma - GINA n.d. https:\/\/ginasthma.org\/2024-report\/ (Accessed April 11, 2025)."},{"key":"777_CR17","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1007\/s12325-023-02514-0","volume":"40","author":"Efficacy of Biologics in Severe","year":"2023","unstructured":"Efficacy of Biologics in Severe. Uncontrolled asthma stratified by blood eosinophil count: A systematic review. Adv Ther. 2023;40:2944\u201364. https:\/\/doi.org\/10.1007\/s12325-023-02514-0.","journal-title":"Adv Ther"},{"key":"777_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02647-2","author":"Efficacy of Biologics in Patients with Allergic Severe Asthma","year":"2023","unstructured":"Efficacy of Biologics in Patients with Allergic Severe Asthma. Overall and by blood eosinophil count: A literature review. Adv Ther. 2023. https:\/\/doi.org\/10.1007\/s12325-023-02647-2.","journal-title":"Adv Ther"},{"key":"777_CR19","doi-asserted-by":"publisher","unstructured":"Long-Term Clinical and sustained remission in severe eosinophilic asthma treated with mepolizumab: the REMI-M study. medRxiv 2024. https:\/\/doi.org\/10.1101\/2024.03.13.24304254","DOI":"10.1101\/2024.03.13.24304254"},{"key":"777_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.11.005","author":"Prospective direct comparison of biological treatments on severe eosinophilic asthma","year":"2023","unstructured":"Prospective direct comparison of biological treatments on severe eosinophilic asthma. Findings from the PRISM study. Ann Allergy Asthma Immunol. 2023. https:\/\/doi.org\/10.1016\/j.anai.2023.11.005.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"777_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.325","author":"A real-world","year":"2024","unstructured":"A real-world. Analysis of key asthma remission components in patients treated with benralizumab: the ZEPHYR-4 study. J Allergy Clin Immunol. 2024. https:\/\/doi.org\/10.1016\/j.jaci.2023.11.325.","journal-title":"J Allergy Clin Immunol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-025-00777-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:58:52Z","timestamp":1767790732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12865-025-00777-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1186\/s12865-025-00777-6","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate is not applicable as this study involves publicly available data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is not applicable as this study involves publicly available data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}